학술논문
A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients
Document Type
Article
Author
Scagliotti, Giorgio; Moro-Sibilot, Denis; Kollmeier, Jens; Favaretto, Adolfo; Cho, Eun Kyung; Grosch, Heidrun; Kimmich, Martin; Girard, Nicolas; Tsai, Chun-Ming; Hsia, Te-Chun; Brighenti, Matteo; Schumann, Christian; Wang, Xuejing Aimee; Wijayawardana, Sameera R.; Gruver, Aaron M.; Wallin, Johan; Mansouri, Kambiz; Wacheck, Volker; Chang, Gee-Chen
Source
In Journal of Thoracic Oncology January 2020 15(1):80-90
Subject
Language
ISSN
1556-0864